Home
Join us in Crested Butte, CO
February 28 – March 3, 2026
HCNMC will be in-person for the 2026 High Country Nuclear Medicine Conference in Crested Butte, CO.
The HCNMC is committed to ensuring that appropriate health and safety protocols are in place for this event. We will follow all Centers for Disease Control and Prevention (CDC) safety protocols and recommendations and will comply with all federal, state and local regulations.
High Country continues to attract and blend experts from academia and industry, with leaders in medical specialties, the regulatory agencies and health care researchers in an informal setting to facilitate dialog and an exchange of ideas. The meeting consists of six to seven hours of structured sessions per day (8 sessions total). In between sessions, roundtable discussions will be held and there are ample opportunities for independent meetings and networking.
Thank you to our 2026 Sponsors!
Featured Sponsors
Bayer is a global life sciences leader in healthcare and nutrition. Building on a 150-year legacy in healthcare, Bayer is committed to improving patient lives by developing therapies and delivering first-in-class educational and support programs to meet their needs.
Bracco Diagnostics Inc. (BDI), the U.S.-based subsidiary of Bracco Imaging SpA, and part of the Bracco Group, is a leader in innovative imaging agents. Bracco offers a product and solution portfolio for all key diagnostic imaging modalities: X-Ray Imaging, Magnetic Resonance Imaging (MRI), Contrast Enhanced Ultrasound (CEUS), and Nuclear Medicine through radioactive tracers. Bracco nuclear medicine offers specialty radiopharmaceuticals for cardiac PET and hepatobilia.
Clarity Pharmaceuticals is a global leader in the development of next-generation diagnostic and therapeutic radiopharmaceuticals with its Targeted Copper Theranostic (TCT) platform of products that utilize the “perfect pairing” of copper-64 for imaging and copper-67 for therapy.
At Curium, we have a singular focus – to develop, manufacture and supply world-class radiopharmaceutical products around the globe. We strive to innovate further in nuclear diagnostics and therapies so we can enhance the lives of people with cancer.
Lantheus is the leading radiopharmaceutical-focused company with proven expertise in developing, manufacturing, and commercializing pioneering diagnostic and therapeutic products and artificial intelligence (AI) solutions.
GE HealthCare’s MIM digital imaging solutions streamline workflows to support precise, personalized care in radiation oncology, molecular imaging, theranostics, and more.
RayzeBio, a Bristol Myers Squibb Company, is a clinical-stage radiopharmaceutical company with a mission to transform the lives of people with cancer. A wholly-owned subsidiary of Bristol Myers Squibb, RayzeBio seeks to improve cancer patient survival by efficiently developing targeted innovative radiopharmaceuticals that harness the power of radioisotopes.
Supporter Sponsors
Blue Earth Diagnostics, an indirect subsidiary of Bracco Imaging S.p.A., is a growing international molecular imaging company focused on delivering innovative, well-differentiated diagnostic solutions that inform patient care. Formed in 2014, the Company’s success is supported by a demonstrated track record of rapid development and commercialization of positron emission tomography (PET) radiopharmaceuticals. For more information, please visit www.blueearthdiagnostics.com.
Contributing Sponsors
